Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Feb;4(1):17-8.
doi: 10.3978/j.issn.2072-1439.2011.06.07.

Drug sensitivity testing for personalized lung cancer therapy

Affiliations

Drug sensitivity testing for personalized lung cancer therapy

Peter W Gout et al. J Thorac Dis. 2012 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest.

Figures

None
Yuzhuo Wang

Similar articles

Cited by

References

    1. Travis WD. Pathology of lung cancer. Clin Chest Med. 2002;23:65–81. - PubMed
    1. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552–9. - PubMed
    1. Higashiyama M, Okami J, Maeda J, Tokunaga T, Fujiwara A, Kodama K, et al. Differences in chemosensitivity between primary and paired metastatic lung cancer tissues: in vitro analysis based on the collagen droplet embedded culture drug test (CD-DST) J Thoracic Dis. 2011;4:40–7. - PMC - PubMed
    1. Dong X, Guan J, English JC, Flint J, Yee J, Evans K, et al. Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy. Clin Cancer Res. 2010;16:1442–51. - PubMed
    1. Toole BP. Hyaluronan-CD44 interactions in cancer: paradoxes and possibilities. Clin Cancer Res. 2009;15:7462–8. - PMC - PubMed